CND Life Sciences, an innovative medical diagnostics company pioneering the detection, visualization, and quantification of protein deposition in cutaneous nerve fibers, has been awarded a $4.2 million grant from the Arizona Governor’s Office to support the creation of the world’s first digital biosignatures laboratory focused on neurodegenerative disorders. Parkinson’s disease and other neurodegenerative conditions place Arizonans and patients nationally at a higher risk for morbidity and mortality if they contract COVID-19.
“Creating a Digital Biosignatures Lab for Neurodegenerative Diseases right here in Scottsdale has the chance to transform how physicians diagnose and treat these debilitating diseases,” said Todd Levine, MD, Chief Medical Officer of CND Life Sciences and Director of Neurology at HonorHealth. “COVID-19 has taught us many things, including that we can accelerate medical innovations to treat vulnerable populations of patients if we put the right resources and vigor behind them,” explained Dr. Levine.” We are truly grateful for the grant support from the State of Arizona and are highly motivated to improve the care of patients locally and beyond.”
CND develops and commercializes skin-based tests to help clinicians accurately diagnose and treat neurologic disorders such as Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, and peripheral neuropathies. These diseases, which affect millions of adults and are often misdiagnosed or identified late in the disease course, are expected to double in prevalence by 2050. At the end of 2019, CND introduced a reliable and minimally invasive technology, the Syn-One Test®, that objectively detects and visualizes the abnormal form of a protein called alpha-synuclein to aid in the diagnosis of these challenging diseases known as synucleinopathies. With the Syn-One Test, CND also applies immunohistopatholgical techniques to identify peripheral nerve degeneration, another critical marker of disease. The next phase of innovation for CND is to incorporate digital technology and artificial intelligence (AI) to augment the pathological reading of tissue specimens and ultimately improve early diagnosis and treatment of these serious disor.
SOURCE: PR Newswire